During its October 5–8, 2015, meetings, the Pharmacovigilance Risk Assessment Committee ("PRAC") discussed three ongoing referrals on SGLT2 inhibitors, human papillomavirus ("HPV") vaccines, and Tysabri. The PRAC did not initiate or conclude a safety referral. A record of the discussions will be provided in the minutes of the meeting, which will be published following the next PRAC meeting in November 2015.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
